Schlackow, I;
Kent, S;
Herrington, W;
Emberson, J;
Haynes, R;
Reith, C;
Collins, R;
... Tomson, C; + view all
(2019)
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Kidney International
, 96
(1)
pp. 170-179.
10.1016/j.kint.2019.01.028.
Preview |
Text
Wheeler_Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease_VoR.pdf - Published Version Download (1MB) | Preview |
Abstract
Statin-based treatments reduce cardiovascular disease (CVD) risk in patients with non-dialysis chronic kidney disease (CKD), but it is unclear which regimen is the most cost-effective. We used the Study of Heart and Renal Protection (SHARP) CKD-CVD policy model to evaluate the effect of statins and ezetimibe on quality-adjusted life years (QALYs) and health care costs in the United States (US) and the United Kingdom (UK). Net costs below $100,000/QALY (US) or £20,000/QALY (UK) were considered cost-effective. We investigated statin regimens with or without ezetimibe 10 mg. Treatment effects on cardiovascular risk were estimated per 1-mmol/L reduction in low-density lipoprotein (LDL) cholesterol as reported in the Cholesterol Treatment Trialists’ Collaboration meta-analysis, and reductions in LDL cholesterol were estimated for each statin/ezetimibe regimen. In the US, atorvastatin 40 mg ($0.103/day as of January 2019) increased life expectancy by 0.23 to 0.31 QALYs in non-dialysis patients with stages 3B to 5 CKD, at a net cost of $20,300 to $78,200/QALY. Adding ezetimibe 10 mg ($0.203/day) increased life expectancy by an additional 0.05 to 0.07 QALYs, at a net cost of $43,600 to $91,500/QALY. The cost-effectiveness findings and policy implications in the UK were similar. In summary, in patients with non-dialysis-dependent CKD, the evidence suggests that statin/ezetimibe combination therapy is a cost-effective treatment to reduce the risk of CVD.
| Type: | Article |
|---|---|
| Title: | Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.kint.2019.01.028 |
| Publisher version: | https://doi.org/10.1016/j.kint.2019.01.028 |
| Language: | English |
| Additional information: | © 2019, International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | chronic kidney disease, cost-effectiveness, ezetimibe, health care costs, quality-adjusted life years, statin |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10078789 |
Archive Staff Only
 |
View Item |
